Research programme: liver X receptor antagonists - Amgen
Latest Information Update: 22 Mar 2010
At a glance
- Originator Amgen
- Class Small molecules
- Mechanism of Action Liver X receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Lipid metabolism disorders
Most Recent Events
- 10 Apr 2008 Preclinical trials in Lipid metabolism disorders in USA (unspecified route)